Company · CIK 0001515673 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Ultragenyx Pharmaceutical Inc. · RARE
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 SForm 4 → | Sep 15, 6:57 pm EDT | Theodore Alan HuizengaSVP, Chief Accounting Officer | 1,283 | $13.57 | $17,410 | 67,863 | −1.86% | 10b5-1 |
| Sep 3, 2026 SForm 4 → | Sep 8, 12:29 pm EDT | Theodore Alan HuizengaSVP, Chief Accounting Officer | 161 | $13.99 | $2,252 | 69,146 | −0.23% | |
| Aug 3, 2026 SForm 4 → | Aug 4, 3:15 pm EDT | Karah Herdman ParschauerEVP and Chief Legal Officer | 1,900 | $24.92 | $47,348 | 92,562 | −2.01% | 10b5-1 |
| Aug 3, 2026 SForm 4 → | Aug 4, 3:13 pm EDT | Howard HornChief Financial Officer | 4,696 | $24.92 | $117,024 | 96,295 | −4.65% | 10b5-1 |
| Jul 1, 2026 SForm 4 → | Jul 6, 3:37 pm EDT | Howard HornChief Financial Officer | 4,698 | $33.13 | $155,645 | 100,991 | −4.45% | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.